Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 136

1.

Assessment of the Need for a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Using a Needs-Based Survey.

Hwa YL, Marshall AL, Shelly JL, Colborn LK, Nowakowski GS, Lacy MQ.

J Oncol Pract. 2019 May 21:JOP1800697. doi: 10.1200/JOP.18.00697. [Epub ahead of print]

PMID:
31112482
2.

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.

Nowakowski GS, Feldman T, Rimsza LM, Westin JR, Witzig TE, Zinzani PL.

Blood Cancer J. 2019 May 16;9(6):48. doi: 10.1038/s41408-019-0208-6. Review.

3.

End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma.

Kostakoglu L, Nowakowski GS.

PET Clin. 2019 Jul;14(3):307-315. doi: 10.1016/j.cpet.2019.03.001. Review.

PMID:
31084771
4.

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML.

JAMA Oncol. 2019 Apr 25. doi: 10.1001/jamaoncol.2019.0393. [Epub ahead of print]

PMID:
31021376
5.

Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.

St-Pierre F, Broski SM, LaPlant BR, Ristow K, Maurer MJ, Macon WR, Habermann TM, Ansell SM, Thompson CA, Micallef INM, Nowakowski GS, Witzig TE.

Am J Hematol. 2019 Apr 21. doi: 10.1002/ajh.25493. [Epub ahead of print]

PMID:
31006875
6.

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.

Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS; Mayo Clinic Histiocytosis Working Group.

Haematologica. 2019 Apr 19. pii: haematol.2019.219626. doi: 10.3324/haematol.2019.219626. [Epub ahead of print]

7.

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators.

J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21.

PMID:
30897038
8.

Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.

Castellino A, Pulido JS, Johnston PB, Ristow KM, Nora Bennani N, Inwards DJ, Macon WR, Micallef INM, King RL, Salomao DR, Witzig TE, Habermann TM, Nowakowski GS.

Am J Hematol. 2019 Mar;94(3):291-298. doi: 10.1002/ajh.25350. Epub 2018 Dec 5.

PMID:
30516868
9.

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.

10.

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia.

Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P.

Leukemia. 2019 Mar;33(3):790-794. doi: 10.1038/s41375-018-0286-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315235
11.

Identification of Factors Associated with Hematology-Oncology Fellow Academic Success and Career Choice.

Marshall AL, Gupta R, Grill D, Mann S, Freidline K, Nowakowski G, Thompson C, Hobday T.

J Cancer Educ. 2018 Sep 28. doi: 10.1007/s13187-018-1432-7. [Epub ahead of print]

PMID:
30267295
12.

Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?

Thanarajasingam G, Maurer MJ, Habermann TM, Nowakowski GS, Bennani NN, Thompson CA, Cerhan JR, Witzig TE.

Nutr Cancer. 2018 Oct;70(7):1088-1090. doi: 10.1080/01635581.2018.1502328. Epub 2018 Sep 20.

PMID:
30235018
13.

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.

Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):664-672.e2. doi: 10.1016/j.clml.2018.06.013. Epub 2018 Jun 15.

PMID:
30104176
14.

A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.

McCarter SJ, Vijayvargiya P, Sidana S, Nault AM, Lane CE, Lehman JS, Wilson JW, Parikh SA, Nowakowski GS, Al-Kali A.

Leuk Lymphoma. 2019 Feb;60(2):559-561. doi: 10.1080/10428194.2018.1494271. Epub 2018 Aug 2. No abstract available.

PMID:
30070153
15.

History of autoimmune conditions and lymphoma prognosis.

Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, Slager SL, Cerhan JR.

Blood Cancer J. 2018 Aug 1;8(8):73. doi: 10.1038/s41408-018-0105-4.

16.

Correction to: The diagnosis and treatment of primary vitreoretinal lymphoma: a review.

Pulido JS, Johnston PB, Nowakowski GS, Castellino A, Raja H.

Int J Retina Vitreous. 2018 Jun 4;4:22. doi: 10.1186/s40942-018-0126-y. eCollection 2018.

17.

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

Ayed AO, Chiappella A, Pederson L, Laplant BR, Congiu AG, Gaidano G, Spina M, Re A, Cavallo F, Musuraca G, Macon WR, Witzig T, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Jun 26;8(7):63. doi: 10.1038/s41408-018-0097-0.

18.

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.

McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.

Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.

19.

T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes.

Kommalapati A, Tella SH, Go RS, Nowakowski GS, Goyal G.

Br J Haematol. 2019 Apr;185(1):140-142. doi: 10.1111/bjh.15391. Epub 2018 May 30. No abstract available.

PMID:
29845599
20.

Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Fama A, Xiang J, Link BK, Allmer C, Klinzman D, Feldman AL, Nowakowski GS, Liebow M, Larson MC, Maurer MJ, Ansell SM, Novak AJ, Asmann YW, Slager SL, Call TG, Habermann TM, Cerhan JR, Stapleton JT.

Br J Haematol. 2018 Sep;182(5):644-653. doi: 10.1111/bjh.15416. Epub 2018 May 29.

PMID:
29808922

Supplemental Content

Loading ...
Support Center